

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM334621

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release (Reel 4305 / Frame 0290)		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
General Electric Capital Corporation		03/09/2015	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	CorePharma, L.L.C		
Street Address:	215 Wood Avenue		
City:	Middlesex		
State/Country:	NEW JERSEY		
Postal Code:	08846		
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE		
Name:	CorePharma, Inc.		
Street Address:	215 Wood Avenue		
City:	Middlesex		
State/Country:	NEW JERSEY		
Postal Code:	08846		
Entity Type:	CORPORATION: DELAWARE		
Name:	CorePharma Holdings, Inc.		
Street Address:	215 Wood Avenue		
City:	Middlesex		
State/Country:	NEW JERSEY		
Postal Code:	08846		
Entity Type:	CORPORATION: DELAWARE		
Name:	Amedra Pharmaceuticals LLC		
Street Address:	2 Walnut Grove Dr., Suite 190		
City:	Horsham		
State/Country:	PENNSYLVANIA		
Postal Code:	19044		
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE		
PROPERTY NUMBERS Total: 9			
Property Type	Number	Word Mark	
Registration Number:	2059777	ALBENZA	
TRADEMARK			

OP \$240.00 2059777

Property Type	Number	Word Mark
Registration Number:	571968	DARAPRIM
Registration Number:	1177791	DEXEDRINE
Registration Number:	652637	SPANSULE
Registration Number:	2781023	
Registration Number:	2351465	COREPHARMA, LLC
Serial Number:	77936227	COREPHARMA
Serial Number:	77936220	COREPHARMA
Serial Number:	77932673	AMEDRA

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: marina.kelly@thomsonreuters.com

Correspondent Name: Doris Ka, Legal Assistant

Address Line 1: 80 Pine Street

Address Line 2: Cahill Gordon & Reindel LLP

Address Line 4: New York, NEW YORK 10005

NAME OF SUBMITTER:	Doris Ka, Legal Assistant
SIGNATURE:	/Marina Kelly, Thomson Reuters/
DATE SIGNED:	03/10/2015

Total Attachments: 8

source=GE CorePharma TM Release 4305 0290 (2)#page1.tif
source=GE CorePharma TM Release 4305 0290 (2)#page2.tif
source=GE CorePharma TM Release 4305 0290 (2)#page3.tif
source=GE CorePharma TM Release 4305 0290 (2)#page4.tif
source=GE CorePharma TM Release 4305 0290 (2)#page5.tif
source=GE CorePharma TM Release 4305 0290 (2)#page6.tif
source=GE CorePharma TM Release 4305 0290 (2)#page7.tif
source=GE CorePharma TM Release 4305 0290 (2)#page8.tif

RECORDATION FORM COVER SHEET TRADEMARKS ONLY

To the Director of the U. S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies):

General Electric Capital Corporation

- Individual(s)
- Partnership
- Corporation- State: Delaware
- Other _____
- Association
- Limited Partnership

Citizenship (see guidelines) _____

Additional names of conveying parties attached? Yes No

3. Nature of conveyance/Execution Date(s) :

Execution Date(s) March 9, 2015

- Assignment
- Security Agreement
- Other Release (Reel 4305 / Frame 0290)
- Merger
- Change of Name

2. Name and address of receiving party(ies)

Additional names, addresses, or citizenship attached? Yes No

Name: CorePharma, L.L.C.

Street Address: 215 Wood Avenue

City: Middlesex

State: NJ

Country: USA Zip: 08846

- Individual(s) Citizenship _____
- Association Citizenship _____
- Partnership Citizenship _____
- Limited Partnership Citizenship _____
- Corporation Citizenship _____
- Limited Liability Company
- Other Delaware - USA Citizenship Delaware - USA

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No
(Designations must be a separate document from assignment)

4. Application number(s) or registration number(s) and identification or description of the Trademark.

A. Trademark Application No.(s) _____ Text _____

B. Trademark Registration No.(s) _____

See Schedule 1

Additional sheet(s) attached? Yes No

C. Identification or Description of Trademark(s) (and Filing Date if Application or Registration Number is unknown):

5. Name & address of party to whom correspondence concerning document should be mailed:

Name: Doris Ka, Legal Assistant

Internal Address: Cahill Gordon & Reindel LLP

Street Address: 80 Pine Street

City: New York

State: NY Zip: 10005

Phone Number: 212) 701-3569

Docket Number: 08380.595

Email Address: dka@cahill.com

6. Total number of applications and registrations involved: 9

7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$ _____

- Authorized to be charged to deposit account
- Enclosed

8. Payment Information:

Deposit Account Number _____

Authorized User Name _____

9. Signature:



Signature

March 10, 2015

Date

Doris Ka, Legal Assistant

Name of Person Signing

Total number of pages including cover sheet, attachments, and document:

8

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Branch, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

ITEM 1 (cont'd)
to Trademarks Recordation Form Cover Sheet
Release of security interest recorded at Reel 4305 / Frame 0290

Conveying Parties

	Entity	Address	Type of Entity	Jurisdiction
1.	General Electric Capital Corporation	500 West Monroe Street Chicago, IL 60661	Corpoation	Delaware

ITEM 2

Additional Receiving Parties

	Entity	Address	Type of Entity	Jurisdiction
1.	CorePharma, Inc.	215 Wood Avenue Middlesex, NJ 08846	Corpoation	Delaware
2.	CorePharma Holdings, Inc.	215 Wood Avenue Middlesex, NJ 08846	Corpoation	Delaware
3.	Amedra Pharmaceuticals LLC	2 Walnut Grove Dr., Suite 190 Horsham, PA 19044	Limited Liability Company	Delaware

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

THIS RELEASE OF SECURITY INTEREST INTELLECTUAL PROPERTY (this "Release") is made as of March 9, 2015 ("Effective Date") by GENERAL ELECTRIC CAPITAL CORPORATION, in its capacity as Administrative Agent ("Grantee"), in favor of COREPHARMA, L.L.C., COREPHARMA, INC., TOWER HOLDINGS, INC. (f/k/a COREPHARMA HOLDINGS, INC.), and AMEDRA PHARMACEUTICALS LLC (each a "Grantor" and, collectively, the "Grantors").

WHEREAS, pursuant to the terms and conditions of that certain Amended and Restated Intellectual Property Security Agreement, dated as of October 22, 2010 (the "October 2010 Agreement"), Grantors assigned, transferred and conveyed to Grantee, and granted to Grantee, a security interest in all of Grantors' right, title and interest in and to the Intellectual Property Collateral (as defined in the October 2010 Agreement, the "Intellectual Property Collateral");

WHEREAS, the October 2010 Security Agreement was recorded with the United States Patent and Trademark Office on October 27, 2010 at Reel 4305, Frame 0290;

WHEREAS, Grantee has consented to the release of the Lien on all of the Intellectual Property Collateral, including but not limited to the trademark listed on Schedule 1 hereto (collectively, the "Released IP Collateral");

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantee hereby covenants and agrees as follows:

1. Grantee's mortgage, pledge, and hypothecation and Lien on and security interest in the Released IP Collateral is hereby terminated and released.

2. To the extent Grantee retains any such interest, Grantee hereby assigns, transfers and conveys to Grantors, all of Grantee's right, title and interest, now owned or hereinafter acquired, that it may have whether by assignment or otherwise, in and to any mortgage and continuing security interest and collateral assignment in the Released IP Collateral. Such assignment, transfer and conveyance by Grantee is made without any representation or warranty (express or implied) by Grantee.

3. Grantee hereby agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions as may be reasonably requested or are required in order to more fully and effectively carry out the purposes of this Release, all at the expense of Grantors.

[the remainder of this page intentionally left blank]

IN WITNESS WHEREOF, Grantee has caused this Release to be executed by its duly authorized representative as of the Effective Date.

GENERAL ELECTRIC CAPITAL
CORPORATION,
as Grantee

By: _____

Name: *Henry Slawson*

Title: *Duly Authorized Signatory*

COREPHARMA, L.L.C.
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY
SIGNATURE PAGE

TRADEMARK
REEL: 005475 FRAME: 0014

Schedule 1

[See attached]

SCHEDULE I
to
INTELLECTUAL PROPERTY SECURITY AGREEMENT

I. PATENT REGISTRATIONS

None.

II. PATENT APPLICATIONS

None.

III. PATENT LICENSES

None.

SCHEDULE II
to
INTELLECTUAL PROPERTY SECURITY AGREEMENT

I. TRADEMARK REGISTRATIONS

US Trademark Reg. No. 2,059,777 for the ALBENZA word mark
US Trademark Reg. No. 571,968 for the DARAPRIM word mark
US Trademark Reg. No. 1,177,791 for the DEXEDRINE word mark
US Trademark Reg. No. 652,637 for the SPANSULE word mark
US Trademark Reg. No. 2,781,023 for the SPANSULE CAPSULE device (the bullet-shaped capsule)
US Trademark Reg. No. 77,936,227 for CorePharma word mark
US Trademark Reg. No. 77,936,220 for CorePharma word mark
US Trademark Reg. No. 2,351,465 for CorePharma, LLC word mark
US Trademark Reg. No. 77,932,673 for Amedra word mark

II. TRADEMARK APPLICATIONS

None.

III. TRADEMARK LICENSES

None.

SCHEDULE III
to
INTELLECTUAL PROPERTY SECURITY AGREEMENT

I. COPYRIGHT REGISTRATIONS

None.

II. COPYRIGHT APPLICATIONS

None.

III. COPYRIGHT LICENSES

None.